Head and Neck Cancer
PV QA 2 - Poster Viewing Q&A 2
MO_31_2731 - Adoption of AJCC 8th Edition for p16+ Oropharynx Cancers May Result in Decreased Utilization of Adjuvant Therapies Due to Shifts in Pathologic Nodal Staging
Monday, October 22
10:45 AM - 12:15 PM
Location: Innovation Hub, Exhibit Hall 3
Adoption of AJCC 8th Edition for p16+ Oropharynx Cancers May Result in Decreased Utilization of Adjuvant Therapies Due to Shifts in Pathologic Nodal Staging
J. Y. Shin, M. Fidler, J. Showel, R. Ghai, P. Gattuso, K. M. Stenson, S. Al-Khudari, and N. Sen; Rush University Medical Center, Chicago, IL
Purpose/Objective(s): The 8th edition of the AJCC (American Joint Committee on Cancer) system no longer includes nodal laterality or size in the pN staging system for p16+ oropharynx cancers. This is because number of involved lymph nodes provides better discriminatory ability for recurrence than laterality, size, or presence of high risk nodal features (i.e. extracapsular extension [ECE]). At our institution, we have routinely offered adjuvant radiotherapy (+/- chemotherapy) for patients with traditional intermediate or high risk features independent of p16 status as per NCCN guidelines. Here, we examine a cohort of p16+ patients staged and treated according to AJCC 7th edition and reclassify them according to the 8th edition to determine rate of nodal downstaging based on the new system.
Materials/Methods: Patients with pathologically node positive p16+ oropharyngeal cancer treated with primary surgery (most commonly TORS with selective neck dissection) followed by adjuvant intensity modulated radiation therapy (+/- chemotherapy) were included for analysis. Demographics, pathology, and treatment details were collected from the electronic medical record. Indications for adjuvant therapy were recorded and patients were re-staged according to the AJCC 8th edition. Rates of nodal downstaging were recorded.
Results: 28 patients met inclusion criteria and were treated from 2012 to 2017. 93% were male. 24 (85%) primaries were tonsillar and 4 (15%) base of tongue. An ipsilateral selective neck dissection was performed in 17 (61%) cases. 27 patients had pre-operative imaging (CT or PET) consistent with nodal involvement. The median number of involved lymph nodes was 2 (range 1-8). 13 (46%) had pathologic evidence of ECE, one (4%) microscopic perineural invasion (PNI), and five (18%) had lymphovascular space invasion (LVSI). Five patients (18%) had a microscopically positive margin. AJCC 7th edition N staging was as follows: N1: 10 (36%), N2a: 1 (4%), and N2b: 17 (60%). 15 of 18 (83%) AJCC 7th N2 patients were downstaged to AJCC 8th N1. Seven of these 15 (47%) patients did not have other adverse pathologic features (i.e. pT3, ECE, positive margin, PNI, LVSI). Radiation therapy was delivered using a simultaneous integrated boost technique in all cases. The median dose to the highest risk volume was 60 Gy (range 60-66 Gy). 13 patients (46%) received concurrent chemotherapy. At a median follow up of 25 months (range 3 months to 10 years), there have been no recurrences in this cohort.
Conclusion: Nodal downstaging from pN2 to pN1 with the adoption of AJCC 8th edition is common for surgically-treated node positive p16+ oropharynx cancer. Although number of positive nodes has high discriminatory ability for recurrence, it is unknown whether the omission of adjuvant therapy in patients with < 5 positive nodes is safe. Until this is known, the decision to recommend adjuvant therapy should be highly dependent on a thorough understanding of pathologic findings rather than relying purely on the new pathologic N stage.
Author Disclosure: J.Y. Shin: None. R. Ghai: None. P. Gattuso: None. K.M. Stenson: None. S. Al-Khudari: None. N. Sen: None.